OBJECTIVE To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists
(RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND …

Aims To determine the potential association between the use of either glucagon‐like peptide‐
1 receptor agonists (GLP‐1RAs) or dipeptidyl peptidase‐4 (DPP‐4) inhibitors, and the risk of …

Aim To conduct a meta‐analysis of randomized clinical trials (RCTs) to investigate whether
there is an association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) …

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective
medications for the treatment of type 2 diabetes and obesity. Pharmacological studies in …

Purpose Some preliminary studies reported a link between GLP-1 receptor agonists (GLP-
1RAs) and thyroid/pancreatic neoplasms, while its human relevance remained …

In this issue of Diabetes Care, Bezin et al.(1) report the findings of a populationbased case-
control study from France on the potential effects of glucagon-like peptide 1 receptor …

The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of
various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship …

Cases of pancreatitis have been described in connection with the use of exenatide (1),
liraglutide (2) and other glucagon-like peptide (GLP)-1 receptor agonists. From these …

Importance Concerns have been raised that glucagon-like peptide-1 receptor agonists (GLP-
1RA) may increase the risk of pancreatic cancer. Objective To investigate the association of …

Although several classes of pharmacotherapy are available for type 2 diabetes, glycaemic
control is often hampered by medication‐related adverse effects and contraindications such …